Urology/Gynecology/G.I.
Urology/Gynecology/G.I
The potential for Uro-gynecological market is mainly due to the enormous increase in burden of uterine pathologies in the last three to four years. The Compound Annual Growth Rate (CAGR) for minimally invasive procedures is consistent at 15-20 percent and this is expected to drive the market and create enormous opportunities for participants.
Ardana PLC
Ardana PLC said it is planning to sell or merge the company in order to increase the shareholder value of its product pipeline. The decision to sell came after a strategic review in December which concluded the company had to concentrate efforts and resources on products that are closer to the market. Ardana stressed that it will scale back its activities to save cash and will halt further development on its Tevelerix LA cancer product and its testosterone cream.
The U.S. Supreme Court
The U.S. Supreme Court ruled that the manufacturer of a medical device approved by the United States cannot be sued under state law if the device causes an injury. The court ruled 8-1 in favor of Medtronic Inc. Riegel and his wife, Donna, sued the company in U.S. court, contending that the catheter had been designed, labeled and manufactured in a way that violated state law, and that those defects had caused severe and permanent injuries to Riegel. But a U.S. District Court and the 2nd U.S.
Boston Scientific Corporation
Boston Scientific Corporation announced U.S. Food and Drug Administration (FDA) approval for three products in its Cardiac Rhythm Management business.
Medtronic Inc
Medtronic Inc. announced financial results for the third quarter and nine months ended January 25, 2008. For the quarter, the company reported net earnings of $77 million or $0.07 diluted earnings per share on net sales of $3,405 million against net earnings of $710 million or $0.61 diluted earnings per share on net sales of $3,048 million for the same period a year ago.
- Login to post comments
Conceptus Inc.
Conceptus Inc. reported earnings results for the fourth quarter and full year ended December 31, 2007. Net sales for the fourth quarter of 2007 were $18.6 million, up 44% over net sales of $12.9 million for the fourth quarter of 2006 and up 13% over net sales of $16.4 million for the third quarter of 2007. The net loss for the fourth quarter of 2007 was $2.8 million, or $0.09 per share, compared with the net loss for the fourth quarter of 2006 of $3.9 million, or $0.13 per share.
Celsion Corp.
Celsion Corp. announced earnings results for the fourth quarter and full year of 2007. The company reported wider losses in the fourth quarter compared with a year ago. The company reported a net loss for the fourth quarter of $2.3 million or 22 cents a share, compared with a loss of $1.1 million, or 10 cents a share, during the same quarter a year ago.
- Login to post comments
Celsion Corp.
Celsion Corp. reported two important milestones in the development of its lead drug ThermoDox(R), and in its transformation to a company totally focused on the development and commercialization of oncology drugs. On January 18th, the FDA notified the company that its Special Protocol Assessment (SPA) submission for Phase III liver cancer had been agreed to.
Medtronic Inc.
Medtronic Inc. announced that its Board of Directors unanimously voted to elect Victor Dzau, M.D., chancellor for Health Affairs at Duke University and president and CEO of the Duke University Health System, to the Board as an independent director. Dr. Dzau is also James B. Duke professor of Medicine and director of Molecular and Genomic Vascular Biology at Duke. Most recently, Dr.
Conceptus Inc.
Conceptus Inc. announced that Todd Sloan joined the company as Vice President of Strategic and Professional Marketing, reporting to Mark Sieczkarek, President and Chief Executive Officer. Mr. Sloan is responsible for the company's strategy process, coordinating and implementing the business development plan and professional marketing of the Essure system for permanent birth control. Mr.
